Douglas Thornton to Humans
This is a "connection" page, showing publications Douglas Thornton has written about Humans.
Connection Strength
1.346
-
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 Dec 20; 21(1):220.
Score: 0.094
-
Productivity Loss Among Opioid and Benzodiazepine Users in the United States: A Medical Expenditure Panel Survey From 2010 to 2019. J Occup Environ Med. 2024 Mar 01; 66(3):226-233.
Score: 0.088
-
Physician perspective on the implementation of risk mitigation strategies when prescribing opioid medications: a qualitative analysis. BMC Health Serv Res. 2023 Oct 31; 23(1):1185.
Score: 0.087
-
Differences in Perceived Threat and Efficacy in Managing Opioid Use Disorder versus Alcohol Use Disorder. Subst Use Misuse. 2023; 58(10):1187-1195.
Score: 0.085
-
Patients prefer free drug disposal options delivered by pharmacists at the point of care: Results of a decision tree analysis of a national factorial vignette panel survey. Int J Drug Policy. 2023 06; 116:104045.
Score: 0.084
-
Evaluating the feasibility of implementing a prescription drug misuse prevention intervention in the community: a mixed methods study. BMC Public Health. 2023 04 21; 23(1):728.
Score: 0.084
-
Intention to get naloxone among?patients prescribed opioids for chronic pain. Harm Reduct J. 2022 Sep 22; 19(1):104.
Score: 0.081
-
Barriers and Facilitators to DATA Waivered Providers Prescribing Buprenorphine: A Qualitative Analysis Applying the Theory of Planned Behavior. Subst Use Misuse. 2022; 57(12):1761-1771.
Score: 0.080
-
Do nursing and pharmacy students practice what they preach on safe drug storage and disposal? A cross-sectional study. Nurse Educ Today. 2021 Dec; 107:105143.
Score: 0.075
-
Does Social Desirability Influence Preceptors' Completion of Student Experiential Evaluations? Am J Pharm Educ. 2020 09; 84(9):ajpe7949.
Score: 0.070
-
Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. Int J Infect Dis. 2020 10; 99:373.
Score: 0.070
-
Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach. Int J Drug Policy. 2020 09; 83:102827.
Score: 0.069
-
Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder. J Subst Abuse Treat. 2020 10; 117:108073.
Score: 0.069
-
Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications. Res Social Adm Pharm. 2021 01; 17(1):2005-2008.
Score: 0.069
-
Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
Score: 0.023
-
Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors. Am J Clin Oncol. 2024 Nov 01; 47(11):517-525.
Score: 0.023
-
Opioid and Non-Opioid Pharmacotherapy Use for Pain Management Among Privately Insured Pediatric Patients With Cancer in the United States. Oncologist. 2024 Feb 02; 29(2):176-184.
Score: 0.022
-
Regional Variation in Opioid-Related Emergency Medical Services Transfers During the COVID-19 Pandemic: An Interrupted Time Series Analysis. Subst Use Addctn J. 2024 Jan; 45(1):74-80.
Score: 0.022
-
Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors. BMC Cancer. 2023 Jul 13; 23(1):655.
Score: 0.021
-
Identifying predictors of generalized anxiety among student pharmacists in response to the COVID-19 pandemic. Curr Pharm Teach Learn. 2023 01; 15(1):34-42.
Score: 0.021
-
Optimization of Opioid Discharge Prescriptions Following Thyroid and Parathyroid Surgery. Otolaryngol Head Neck Surg. 2023 Jul; 169(1):176-184.
Score: 0.021
-
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
Score: 0.018
-
Trends and patterns in the use of opioids among metastatic breast cancer patients. Sci Rep. 2020 Dec 10; 10(1):21698.
Score: 0.018
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.017
-
Prolonged Opioid Use After Surgery for Early-Stage Breast Cancer. Oncologist. 2020 Oct; 25(10):e1574-e1582.
Score: 0.017
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.017